ZA975380B - Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors. - Google Patents

Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors.

Info

Publication number
ZA975380B
ZA975380B ZA9705380A ZA975380A ZA975380B ZA 975380 B ZA975380 B ZA 975380B ZA 9705380 A ZA9705380 A ZA 9705380A ZA 975380 A ZA975380 A ZA 975380A ZA 975380 B ZA975380 B ZA 975380B
Authority
ZA
South Africa
Prior art keywords
bicyclic
tyrosine kinase
kinase inhibitors
aralkylaminopyrimidine
derivatives
Prior art date
Application number
ZA9705380A
Other languages
English (en)
Inventor
Maria Gabriella Brasca
Dario Ballinari
Antonio Longo
Franco Buzzetti
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of ZA975380B publication Critical patent/ZA975380B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA9705380A 1996-06-21 1997-06-18 Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors. ZA975380B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9613021.6A GB9613021D0 (en) 1996-06-21 1996-06-21 Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
ZA975380B true ZA975380B (en) 1998-01-05

Family

ID=10795666

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9705380A ZA975380B (en) 1996-06-21 1997-06-18 Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors.

Country Status (20)

Country Link
US (1) US6057326A (de)
EP (1) EP0853616B1 (de)
JP (1) JPH11511761A (de)
KR (1) KR19990043993A (de)
CN (1) CN1198158A (de)
AR (1) AR008614A1 (de)
AT (1) ATE205836T1 (de)
AU (1) AU3094197A (de)
BR (1) BR9702328A (de)
CA (1) CA2228492C (de)
DE (1) DE69706823T2 (de)
EA (1) EA199800215A1 (de)
ES (1) ES2165061T3 (de)
GB (1) GB9613021D0 (de)
HU (1) HUP9902026A3 (de)
IL (1) IL123124A0 (de)
NO (1) NO980718L (de)
PL (1) PL325122A1 (de)
WO (1) WO1997049689A1 (de)
ZA (1) ZA975380B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6347480B1 (en) * 1997-07-07 2002-02-19 Southpac Trust International, Inc. Method for wrapping a floral grouping with a sheet of material constructed of paper and having printed and embossed patterns thereon
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6608060B1 (en) 1996-12-18 2003-08-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
EE05345B1 (et) * 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
SV2002000205A (es) * 1999-11-01 2002-06-07 Lilly Co Eli Compuestos farmaceuticos ref. x-01095
PT1244647E (pt) 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
IL151626A0 (en) 2000-04-07 2003-04-10 Astrazeneca Ab Quinazoline compounds
US20040235867A1 (en) * 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
KR100468352B1 (ko) * 2002-09-24 2005-01-27 한국과학기술연구원 신규 피라졸로피리미딘계 유도체, 그의 제조방법 및 이를 유효성분으로 하는 약학적 조성물
JP2007502776A (ja) * 2003-08-15 2007-02-15 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｒｔｋ阻害剤としての６−置換アニリノプリン類
CA2557433C (en) * 2004-02-19 2013-05-14 Rexahn Corporation Quinazoline derivatives and therapeutic use thereof
US7151176B2 (en) * 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
WO2006104971A1 (en) * 2005-03-28 2006-10-05 Bristol-Myers Squibb Company Atp competitive kinase inhibitors
WO2010054285A2 (en) 2008-11-10 2010-05-14 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
UA110113C2 (xx) * 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
JP5961187B2 (ja) * 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
EP3947390A4 (de) * 2019-04-03 2022-11-30 Mitokinin, Inc. Zusammensetzungen und verfahren zur ihrer verwendung für die behandlung von neurodegenerativer und mitochondrialer erkrankung

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89028A0 (en) * 1988-01-29 1989-08-15 Lilly Co Eli Quinoline,quinazoline and cinnoline derivatives
ZA902280B (en) * 1989-03-29 1990-12-28 Merrell Dow Pharma Selective adenosine receptor agents
JP2762430B2 (ja) * 1991-01-18 1998-06-04 宇部興産株式会社 アラルキルアミノピリミジン類の製法
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JPH06172321A (ja) * 1992-10-08 1994-06-21 Agro Kanesho Co Ltd 置換アミノピリミジン誘導体、その製造法及びそれを有効成分とする有害生物駆除剤
GB9313638D0 (en) * 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
GB9326136D0 (en) * 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
GB9406137D0 (en) * 1994-03-28 1994-05-18 Erba Carlo Spa N-substituted beta-aryl- and betaheteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation
GB9412719D0 (en) * 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
GB9423997D0 (en) * 1994-11-28 1995-01-11 Erba Carlo Spa Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation

Also Published As

Publication number Publication date
PL325122A1 (en) 1998-07-06
GB9613021D0 (en) 1996-08-28
MX9801408A (es) 1998-05-31
WO1997049689A1 (en) 1997-12-31
EP0853616B1 (de) 2001-09-19
IL123124A0 (en) 1998-09-24
ATE205836T1 (de) 2001-10-15
CN1198158A (zh) 1998-11-04
HUP9902026A2 (hu) 2000-04-28
AR008614A1 (es) 2000-02-09
KR19990043993A (ko) 1999-06-25
ES2165061T3 (es) 2002-03-01
CA2228492C (en) 2007-05-08
EP0853616A1 (de) 1998-07-22
NO980718D0 (no) 1998-02-20
DE69706823T2 (de) 2002-04-11
BR9702328A (pt) 1999-07-20
AU3094197A (en) 1998-01-14
US6057326A (en) 2000-05-02
HUP9902026A3 (en) 2000-07-28
NO980718L (no) 1998-04-08
CA2228492A1 (en) 1997-12-31
DE69706823D1 (en) 2001-10-25
EA199800215A1 (ru) 1998-08-27
JPH11511761A (ja) 1999-10-12

Similar Documents

Publication Publication Date Title
IL127796A0 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AU3693697A (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
GB9604361D0 (en) 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
HUS1700048I1 (hu) Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai
IL137041A0 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AU2396897A (en) 5-aminopyrazoles useful as selective inhibitors of the protein tyrosine kinase p56ick
EG24381A (en) Tyrosine kinase inhibitors
AU8689298A (en) Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
GB9613021D0 (en) Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
PL346934A1 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
GB9501567D0 (en) Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
AU7289696A (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
GB9507298D0 (en) Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
HUP9901155A3 (en) Quinazoline derivatives as vegf inhibitors
EP0608897A3 (en) Tyrosine kinase inhibitors and benzoylacrylamide derivatives.
AU2437900A (en) Piperidinylquinolines as protein tyrosine kinase inhibitors
CY2451B1 (en) Fused heterocyclic compunds as protein tyrosine kinase inhibitors.
HU9700344D0 (en) Substituted quinazoline derivatives
CY2380B1 (en) Pde IV inhibiting 2-cyanoiminoimidazole derivatives.
ZA975986B (en) N-alkoxyadenine derivatives acting as cytokine inhibitors.
GB9611797D0 (en) Substituted quinolylmethylen-oxindole analogues as tyrosine kinase inhibitors
GB9610964D0 (en) Substituted tetralylmethylen-oxindole analogues as tyrosine kinase inhibitors
GB9600997D0 (en) N-indolinyl-pyridopyrimidines as tyrosine kinase inhibitors
GB9524131D0 (en) Pyrido-pyrimidine compounds as tyrosine kinase inhibitors
HK1044939A (en) Tyrosine kinase inhibitors